뉴스벤징가
Novocure Brain Cancer Study Shows No Significant Survival Benefit, Stock Tanks
· 발표
기사 요약
Novocure's Phase 3 TRIDENT trial missed its primary survival endpoint in glioblastoma but confirmed TTFields safety.
기사 원문에서 발췌했어요.Novocure's Phase 3 TRIDENT trial missed its primary survival endpoint in glioblastoma but confirmed TTFields safety.
기사 원문에서 발췌했어요.
댓글 —
댓글을 불러오고 있어요…